MDGE.F Stock Overview
A biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Medigene AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.59 |
| 52 Week High | €5.68 |
| 52 Week Low | €2.19 |
| Beta | 0.91 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -67.71% |
| 5 Year Change | -80.05% |
| Change since IPO | -69.53% |
Recent News & Updates
Recent updates
Shareholder Returns
| MDGE.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 2.5% | 1.0% |
| 1Y | n/a | 15.6% | 31.4% |
Return vs Industry: Insufficient data to determine how MDGE.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how MDGE.F performed against the US Market.
Price Volatility
| MDGE.F volatility | |
|---|---|
| MDGE.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MDGE.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine MDGE.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 87 | Selwyn Ho | www.medigene.com |
Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company’s end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer.
Medigene AG Fundamentals Summary
| MDGE.F fundamental statistics | |
|---|---|
| Market cap | US$25.79m |
| Earnings (TTM) | -US$16.77m |
| Revenue (TTM) | US$7.84m |
3.3x
P/S Ratio-1.5x
P/E RatioIs MDGE.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MDGE.F income statement (TTM) | |
|---|---|
| Revenue | €7.45m |
| Cost of Revenue | €1.49m |
| Gross Profit | €5.95m |
| Other Expenses | €21.89m |
| Earnings | -€15.93m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.08 |
| Gross Margin | 79.94% |
| Net Profit Margin | -213.98% |
| Debt/Equity Ratio | 0% |
How did MDGE.F perform over the long term?
See historical performance and comparison